🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

U.S. FDA allows importing of 2 million baby formula cans from UK

Published 05/24/2022, 05:36 PM
Updated 05/24/2022, 07:10 PM
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly
ABT
-

By Ahmed Aboulenein and Ananya Mariam Rajesh

WASHINGTON (Reuters) -The U.S. Food and Drug Administration is easing regulations to allow infant formula imports from Britain, a move it said on Tuesday would bring around 2 million cans onto empty shelves by June to ease a nationwide shortage.

The FDA said it was "exercising enforcement discretion" to allow Britain-based Kendal Nutricare to import certain infant formula products under the Kendamil brand that it has no safety or nutrition concerns over following an evaluation.

"Under the agency's recent increased flexibilities regarding importation of certain infant formula products, the company initially estimates that about 2 million cans of infant formula are expected to land on U.S. store shelves beginning in June," it said in a statement.

Kendal has 40,000 cans in stock for immediate dispatch that the Department of Health and Human Services is working on bringing into the United States as soon as possible, the FDA said.

"We continue to do everything in our power as part of the all-of-government efforts to ensure there's adequate infant formula available wherever and whenever parents and caregivers need it," said FDA Commissioner Robert Califf.

The United States is experiencing one of the biggest infant formula shortages in recent history after Abbott Laboratories (NYSE:ABT) in February recalled some products including Similac and closed its manufacturing plant in Sturgis, Michigan.

Abbott, the biggest U.S. supplier of powder baby formula, shut its facility after reports of bacterial infections among four infants. It exacerbated a shortage among multiple manufacturers that began with supply-chain issues tied to the coronavirus pandemic.

The FDA said it would allow the release of about 300,000 cans of Abbott's EleCare amino acid-based formula for children who urgently need it to survive, on a case-by-case basis.

EleCare was previously produced at the Sturgis facility but were not part of the recall, the FDA said.

Abbott plans to restart production at the facility on June 4, it said in a statement, adding it would prioritize making EleCare and supplying it on or about June 20. Abbott said it would provide the formula to children in need for free.

© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

U.S. President Joe Biden's administration has sought to relieve the shortage by importing emergency supplies from Europe, the first of which arrived earlier this week. Biden invoked the Cold War-era Defense Production Act to help boost supplies.

The FDA said on Tuesday it was in discussion with other manufacturers over additional supplies and that it would prioritize products that demonstrate safety, nutritional adequacy, and are available in large quantities.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.